Drug Profile


Alternative Names: UTL 5g

Latest Information Update: 15 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 21st Century Therapeutics
  • Developer 21st Century Therapeutics; Chengdu Xin Fanyu Biomedical; Sichuan New Phiaring Bio-medical Science
  • Class Chemoprotectants; Isoxazoles; Radioprotectives; Small molecules
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chemotherapy-induced damage; Radiation injuries; Sepsis

Most Recent Events

  • 15 Sep 2016 Chemical structure information added
  • 30 Jun 2014 Preclinical trials in Sepsis in China (unspecified route)
  • 30 Jun 2014 Preclinical trials in Sepsis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top